VEN+AZA-5

Phase 2Small molecule

UUniversity of Leipzig

VEN+AZA-5 is one of 18 small molecule programs targeting Induction Therapy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Induction TherapyRecruiting

Induction TherapyPhase 2

Recruiting

Competition

Competitive Landscape

18 competitors in Induction Therapy

#DrugCompanyPhaseTrials

Venclexta

AbbVie

Phase 2

3 2

Cytosar

Teva

Phase 2

3 3

Xospata

Astellas

Phase 2

1 4

Nexavar

Bayer

Phase 2

1 5

Almonertinib

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 3

1 6

Vepesid

AAvyxa

Phase 2

4 7

Ayvakit

BBlueprint Medicines

Phase 2

1 8

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

1 9

Liposomal Irinotecan

Astellas

Phase 2

1 10

FOLFIRI

Amgen

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Induction Therapy1 trial

Venetoclax in Combination with 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy

Recruiting·UUniversity of Leipzig·Phase 2·NCT05833438·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for VEN+AZA-5. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VEN+AZA-5 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VEN+AZA-5. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Leipzig company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Leipzig

VEN+AZA-5

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Induction Therapy1 trial

References

Drug Info

Quick Facts

Related News